

Clinical Trial Protocol

Iranian Registry of Clinical Trials

12 Jun 2026

Comparing the impact of Metolazone plus Furosemide versus Hydrochlorothiazide Plus Furosemide in Patients with Heart failure and refractory edema: A Randomized clinical trial.

Protocol summary

Registration timing: **registered_while_recruiting**

Study aim

Comparison of Metolazone/Furosemide with Hydrochlorothiazide/Furosemide on diuretic resistance break and improving clinical symptoms.

Last update: **2020-07-25, 1399/05/04**

Update count: **0**

Registration date

2020-07-25, 1399/05/04

Design

Clinical trial with control group, with parallel group design, not blind, randomized, phase 1-2, with a sample size of 50 patients. Randomization was performed as a systematic randomization by numbers obtained from GraphPad online software considering 2 groups of 25 people (intervention and control) by an independent person.

Registrant information

Name

Taher Entezari-Maleki

Name of organization / entity

Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 6695 4709

Email address

tentezarimaleki@razi.tums.ac.ir

Settings and conduct

The study site was the VIP section of the Shahid Madani Research and Treatment Center in Tabriz. There will be no blinding in the study.

Recruitment status

Recruitment complete

Funding source

Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients with diastolic heart failure and refractory edema; age of 18-80 years old; GFR>30; Filling the consent form. Non-inclusion criteria: Renal dysfunction (creatinine clearance of <30 ml/min); History of end-stage renal failure or dialysis; Contraindications for Metolazone and Hydrochlorothiazide; Cardiogenic shock; Acute myocardial infarction; Hypoalbuminemia

Expected recruitment start date

2019-11-26, 1398/09/05

Expected recruitment end date

2020-10-21, 1399/07/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Intervention groups

Intervention group will Metolazone 2.5 and patients in the control group will receive only routine treatment.

Scientific title

Comparing the impact of Metolazone plus Furosemide versus Hydrochlorothiazide Plus Furosemide in Patients with Heart failure and refractory edema: A Randomized clinical trial.

Main outcome variables

Edema; Fluid Input/Output; Sodium (Na); Potassium (K)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20111206008307N35**

Registration date: **2020-07-25, 1399/05/04**

Public title

The effect of Metolazone and Hydrochlorothiazide in refractory edema

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Patients with diastolic heart failure and refractory edema
Glomerular I filtration rate (GFR) > 30

Exclusion criteria:

Renal dysfunction (creatinine clearance <30 ml/min)
History of end-stage renal failure or dialysis
Acute myocardial infarction
Cardiogenic shock
Contraindications for metolazone and hydrochlorothiazide
Hypoalbuminemia
Patients who are not satisfied

Age

From **18 years** old to **80 years** old

Gender

Both

Phase

1-2

Groups that have been masked

No information

Sample size

Target sample size: **50**

More than 1 sample in each individual

Number of samples in each individual: **1**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization was done using computer generated random number (systematic randomization) by online Graphpad software by determining 2 study groups and 25 patients in each group (Control and Intervention) by an independent person.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethic Committee of Tabriz Univercity of Medical Science

Street address

Reasearch and Technology Deputy, Tabriz University of Medical Science, Golgasht Street, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Approval date

2019-11-26, 1398/09/05

Ethics committee reference number

IR.TBZMED.REC.1398.895

Health conditions studied**1****Description of health condition studied**

Systolic and diastolic heart failure

ICD-10 code

I50.4

ICD-10 code description

Combined systolic (congestive) and diastolic (congestive) heart failure

Primary outcomes**1****Description**

Fluid Input/Output

Timepoint

Daily

Method of measurement

Urine bag

2**Description**

Sodium (Na)

Timepoint

Daily

Method of measurement

Laboratory test

3**Description**

Edema

Timepoint

Daily

Method of measurement

Physical examination

4**Description**

Potassium (K)

Timepoint

Daily

Method of measurement

Laboratory test

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Will receive furosemide with Metolazone one 2.5 mg tablet daily, product of Teofarma Pharmaceutical Company, until improving clinical symptoms.

Category

Treatment - Drugs

2

Description

Control group: Will only receive standard treatments (Hydrochlorothiazide with Furosemide).

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Shahid Madani Heart Center of Tabriz

Full name of responsible person

Dr. Taher Entezari-Malek

Street address

Shahid Madani Heart Center, Daneshgah Street, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5166614766

Phone

+98 41 3334 4798

Email

tentezari@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Dr.Mohammad Samiei

Street address

Golgasht, Daneshgah street, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5165665931

Phone

+98 41 3335 7310

Email

Samiei.moh@gmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tabriz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Dr. Taher Entezari-maleki

Position

Associated professor of Clinical pharmacy

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Shahid Madani Center, Daneshgah Street,Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5166414766

Phone

+98 41 3335 5983

Email

tentezari@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Dr.Taher Entezari-Maleki

Position

Associated professor of Clinical pharmacy

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Daneshgah Street, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5166414766

Phone

+98 41 3335 5983

Email

tentezari@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Dr. Taher Entezari-Maleki

Position

Associated professor of Clinical pharmacy

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Daneshgah Street, Tabriz

City

Tabriz

Province

East Azarbaijan

Postal code

5166414766

Phone

+98 41 3335 5983

Email

tentezari@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

All of the data of an article can be published after making patients unrecognized.

When the data will become available and for how long

After publishing of article until 6 months after publishing of the results

To whom data/document is available

Data will be available to researchers working in academic and scientific institutions.

Under which criteria data/document could be used

Researchers that request data will be permitted only to doing analysis according to ethics for scientific aims.

From where data/document is obtainable

Applicants can receive data by sending an E-mail to address of tentezari@gmail.com and get response from Dr. Taher Entezari Maleki.

What processes are involved for a request to access data/document

After contacting with corresponding author (Dr. Taher Entezari Maleki), data will be sent to Tabriz Shahid Madani hospital ethics committee and after receiving permission, data will be sent to applicants.

Comments